We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+4.31%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.43B
AUM Growth
+$292M
Cap. Flow
+$65.8M
Cap. Flow %
4.59%
Top 10 Hldgs %
64.89%
Holding
82
New
14
Increased
33
Reduced
12
Closed
20
Avg Time Held Equity + Options
1.2 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
1.3 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
CYH icon
Community Health Systems
CYH
+$37.3M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$35M
3
AMRN icon
Amarin Corp
AMRN
+$19.9M
4
AMED icon
Amedisys
AMED
+$19.4M
5
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$14.7M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$77.7M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$27.1M
3
NVST icon
Envista
NVST
+$21.6M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$17.9M
5
HLN icon
Haleon
HLN
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 76.06%
2 Miscellaneous 22.43%
3 Financials 0.95%
4 Communication Services 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
EOLS icon
51
Evolus
EOLS
$485M
$1.87M 0.13%
221,551
-492,223
-69% -$4.45M
2022 Q4
1 quarter
A icon
52
Agilent Technologies
A
$49.3B
$1.81M 0.13%
13,110
+1,232
+10% +$180K
2020 Q4
9 quarters
GOSS icon
53
Gossamer Bio
GOSS
$54.1M
$1.7M 0.12%
16,901
+14,973
+777% +$2.29M
2021 Q3
6 quarters
RVTY icon
54
Revvity
RVTY
$17.2B
$1.64M 0.11%
12,335
+1,157
+10% +$152K
2021 Q3
6 quarters
PRTK
55
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.62M 0.11%
+638,474
New +$1.26M
2023 Q1
0 quarters
ARGX icon
56
argenx
ARGX
$51.6B
$1.43M 0.1%
3,836
+360
+10% +$133K
2021 Q3
6 quarters
AFMD icon
57
DELISTED
Affimed
AFMD
$1.4M 0.1%
188,378
+155,356
+470% +$1.55M
2022 Q2
3 quarters
JBIO icon
58
Jade Biosciences
JBIO
$855M
$1.01M 0.07%
1,435
-1,172
-45% -$972K
2022 Q4
1 quarter
RGEN icon
59
Repligen
RGEN
$11.2B
$952K 0.07%
5,656
-51,348
-90% -$9.16M
2021 Q1
8 quarters
WHWK icon
60
Whitehawk Therapeutics
WHWK
$169M
$738K 0.05%
101,918
– –
2022 Q1
4 quarters
NAMS icon
61
NewAmsterdam Pharma
NAMS
$2.42B
$608K 0.04%
+45,856
New +$579K
2023 Q1
0 quarters
ACIU icon
62
AC Immune
ACIU
$242M
$292K 0.02%
124,589
– –
2021 Q3
6 quarters
APLS icon
63
DELISTED
Apellis Pharmaceuticals
APLS
– –
-154,796
Closed -$8M –
BOLT icon
64
Bolt Biotherapeutics
BOLT
$8.09M
– –
-1,559
Closed -$40.5K –
CABA icon
65
Cabaletta Bio
CABA
$251M
– –
-282,874
Closed -$2.62M –
CYH icon
66
CALL
Community Health Systems
CYH
$426M
– –
-312,900
Closed -$1.35M –
ELDN icon
67
Eledon Pharmaceuticals
ELDN
$179M
– –
-67,743
Closed -$154K –
FATE icon
68
Fate Therapeutics
FATE
$225M
– –
-43,562
Closed -$440K –
CBIO icon
69
Crescent Biopharma
CBIO
$455M
– –
-1,006
Closed -$305K –
GSK icon
70
CALL
GSK
GSK
$99.6B
– –
-2,093,700
Closed -$73.6M –
HLN icon
71
Haleon
HLN
$44.1B
– –
-1,881,470
Closed -$15.1M –
INCY icon
72
Incyte
INCY
$23.1B
– –
-63,996
Closed -$5.14M –
MRK icon
73
CALL
Merck
MRK
$362B
– –
-48,700
Closed -$5.4M –
NVST icon
74
Envista
NVST
$3.74B
– –
-642,405
Closed -$21.6M –
PLRX icon
75
Pliant Therapeutics
PLRX
$59.5M
– –
-137,423
Closed -$2.66M –
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Eversept Partners held 82 positions worth $1.43B, up 26% from $1.14B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Eversept Partners deployed $65.8M of net new capital in Q1 2023, opening 14 new positions and adding to 33 existing holdings. Its largest new stake was Amedisys: 224,263 shares worth $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $27.1M trimmed.

  • Eversept Partners's largest Q1 2023 buy was Amedisys: 224,263 shares worth $16.5M.
  • Eversept Partners added most to Community Health Systems in Q1 2023, an estimated $37.3M increase.
  • Eversept Partners's biggest Q1 2023 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $27.1M.
  • Eversept Partners fully exited Sanofi in Q1 2023, selling an estimated $77.7M.
  • Eversept Partners's ten largest holdings make up 65% of its $1.43B portfolio in Q1 2023.
  • Eversept Partners opened 14 new positions and closed 20 in Q1 2023.
  • Eversept Partners's portfolio value rose 26% quarter-over-quarter to $1.43B.

Based on Eversept Partners's 13F filing for Q1 2023, filed 15 May 2023.